- Conditions
- Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Metastatic Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Antiandrogen, SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Chapel Hill, North Carolina
Breast Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced May 21, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
How Breast Cancer studies are organized in the registry
Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.
- 16% of the 1,618 locally indexed Breast Cancer records are currently marked recruiting.
- The most common phase group in the local index is Phase 2 (553 records).
- The most frequent sponsor is Memorial Sloan Kettering Cancer Center (87 records).
- The most listed study location is New York, New York (346 records).
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Phase distribution
Top locations
Top sponsors
Top therapies
Indexed official records
Open in full search- Conditions
- Breast Cancer
- Interventions
- Moderately Hypofractionated Radiation, Ultrahypofractionated Radiation
- Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 768 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Loveland, Colorado • Voorhees Township, New Jersey • Houston, Texas + 1 more
- Conditions
- Breast Cancer
- Interventions
- Quality-of-life Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Axatilimab (SNDX-6352), Cyclophosphamide, Retifanlimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin hydrochloride, Epirubicin hydrochloride, Olaparib, Paclitaxel, Patritumab deruxtecan, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
- Conditions
- Breast Cancer, Breast Cancer Stage IV, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms
- Interventions
- Cryoablation, Pembrolizumab
- Device · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Cancer, Breast Neoplasms, Cancer-related Cognitive Dysfunction
- Interventions
- Aerobic Exercise Training, Health Education (Active comparator)
- Behavioral · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Breast Cancer
- Interventions
- Oncoplastic Breast Surgery
- Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2045
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Melrose, Massachusetts
- Conditions
- Breast Cancer, Postoperative Recovery
- Interventions
- ERAS Protocol, Standard Perioperative Care
- Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Inavolisib, Placebo, Ribociclib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Marshall, Minnesota • Aberdeen, South Dakota • Mitchell, South Dakota + 3 more
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Multiple Myeloma, Prostate Cancer
- Interventions
- mHealth Intervention
- Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, GDC-4198, Giredestrant
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 13 more
About this Breast Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Breast Cancer.